Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages 987-996

  Tatokoro, Manabu ^a   Koga, Fumitaka ^a   Yoshida, Soichiro ^a   Kawakami, Satoru ^a   Fujii, Yasuhisa ^a   Neckers, Len ^b   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

bladder cancer; cisplatin resistance; Hsp90 inhibitors; tumor initiating cell

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALVESPIMYCIN; CISPLATIN; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER INITIATING CELL; BLADDER CARCINOGENESIS; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER RESISTANCE; CELL POPULATION; CELL RENEWAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; FLOW CYTOMETRY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED ICR; MICE, SCID; URINARY BLADDER NEOPLASMS;

EID: 84856934940     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26475     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, Pagano F,. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999; 161: 1494-7. (Pubitemid 29420803)
3. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Sr Trump D,. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9. (Pubitemid 27289886)
4. Dean M, Fojo T, Bates S,. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84. (Pubitemid 40488633)
5. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM,. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44. (Pubitemid 44623625)
6. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP,. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008; 15: 947-58. (Pubitemid 351712600)
7. Tang C, Ang BT, Pervaiz S,. Cancer stem cell: target for anti-cancer therapy. FASEB J 2007; 21: 3777-85. (Pubitemid 350232335)
8. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-9.
9. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN,. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60. (Pubitemid 44949604)
10. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009; 69: 2887-95.
11. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104: 10158-63. (Pubitemid 47175279)
12. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE,. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8. (Pubitemid 24067706)
13. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB,. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401. (Pubitemid 39551674)
14. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8. (Pubitemid 36418143)
15. O'Brien CA, Pollett A, Gallinger S, Dick JE,. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10. (Pubitemid 46067310)
16. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM,. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
17. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr., Chang HY, van de Rijn M, Shortliffe L, Weissman IL,. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009; 106: 14016-21.
18. Neckers L, Neckers K,. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 2002; 7: 277-88. (Pubitemid 35291458)
19. Koga F, Kihara K, Neckers L,. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009; 29: 797-807.
20. Wang Y, Trepel JB, Neckers LM, Giaccone G,. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 2010; 11: 1466-76.
21. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM,. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994; 91: 8324-8.
22. Isaacs JS, Xu W, Neckers L,. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213-7. (Pubitemid 37443877)
23. Korkaya H, Paulson A, Iovino F, Wicha MS,. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-30.
24. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10: R10.
25. Kakuya T, Yamada T, Yokokawa M, Ueda T,. Establishment of cell strains from human urothelial carcinoma and their morphological characterization. In Vitro 1983; 19: 591-9. (Pubitemid 15218471)
26. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, Ando N, Takizawa T, Kageyama Y, Kihara K,. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003; 9: 5501-7. (Pubitemid 37499468)
27. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
28. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC,. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-20.
29. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J,. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973; 11: 765-73.
30. Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovitski E, Trink B, Kihara K,. Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res 2009; 69: 9263-70.
31. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z,. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-12. (Pubitemid 36712932)
32. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX,. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 278: 19245-56. (Pubitemid 36799316)
33. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D,. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002; 62: 5703-10. (Pubitemid 35204725)
34. Sawada M, Okudaira Y, Matsui Y, Nishiura H, Yanagida T,. Pharmacokinetics of cis-platinum diammine dichloride. Gan To Kagaku Ryoho 1982; 9: 55-65.
35. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM,. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005; 56: 126-37. (Pubitemid 40884268)
36. Johnstone RW, Cretney E, Smyth MJ,. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999; 93: 1075-85. (Pubitemid 29067874)
37. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32. (Pubitemid 37328811)
38. Koga F, Tsutsumi S, Neckers LM,. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 2007; 6: 1393-402. (Pubitemid 47327975)
39. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K,. Potential role of heat shock protein 90 inhibitors to overcome chemoradiotherapy resistance associated with HER-2 and NF-kB overexpression in muscle-invasive bladder cancer. Eur Urol Suppl 2011; 10: 167.
40. Toole BP,. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-39. (Pubitemid 38868622)
41. Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P,. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem 2006; 281: 14026-40. (Pubitemid 43848329)
42. Simpson MA, Wilson CM, McCarthy JB,. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 2002; 161: 849-57. (Pubitemid 34988372)
43. Josefsson A, Adamo H, Hammarsten P, Granfors T, Stattin P, Egevad L, Engstrom Laurent A, Wikstrom P, Bergh A. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma and this response is associated with tumor growth and an unfavorable outcome. Am J Pathol 2011; 179: 1961-68.
44. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN,. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008; 26: 3027-36.
45. McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO, Erlichman C,. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 2008; 7: 3256-64.
46. Whitesell L, Lindquist SL,. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72. (Pubitemid 41400776)
47. Takayama S, Reed JC, Homma S,. Heat-shock proteins as regulators of apoptosis. Oncogene 2003; 22: 9041-7. (Pubitemid 38121704)
48. Zoubeidi A, Chi K, Gleave M,. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16: 1088-93.
49. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M,. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007; 6: 299-308. (Pubitemid 46206694)
50. Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE,. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 2010; 10: 481.